Dynavax/$DVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dynavax
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Ticker
$DVAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
405
ISIN
US2681582019
Website
Dynavax Metrics
BasicAdvanced
$1.3B
-
-$0.47
1.26
-
Price and volume
Market cap
$1.3B
Beta
1.26
52-week high
$14.63
52-week low
$9.22
Average daily volume
1.8M
Financial strength
Current ratio
11.933
Quick ratio
9.672
Long term debt to equity
65.282
Total debt to equity
54.64
Interest coverage (TTM)
-0.17%
Profitability
EBITDA (TTM)
3.535
Gross margin (TTM)
60.52%
Net profit margin (TTM)
-20.39%
Operating margin (TTM)
-0.39%
Effective tax rate (TTM)
-8.19%
Revenue per employee (TTM)
$730,000
Management effectiveness
Return on assets (TTM)
-0.07%
Return on equity (TTM)
-10.45%
Valuation
Price to revenue (TTM)
4.762
Price to book
2.54
Price to tangible book (TTM)
2.54
Price to free cash flow (TTM)
25.971
Free cash flow yield (TTM)
3.85%
Free cash flow per share (TTM)
41.97%
Growth
Revenue change (TTM)
24.76%
Earnings per share change (TTM)
-792.73%
3-year revenue growth (CAGR)
-14.42%
10-year revenue growth (CAGR)
43.14%
3-year earnings per share growth (CAGR)
-14.59%
10-year earnings per share growth (CAGR)
-19.07%
What the Analysts think about Dynavax
Analyst ratings (Buy, Hold, Sell) for Dynavax stock.
Bulls say / Bears say
Dynavax's HEPLISAV-B vaccine achieved record Q1 2025 net product revenue of $65 million, marking a 36% year-over-year increase and capturing a 43% U.S. market share. (stocktitan.net)
Analysts have set a consensus 12-month price target of $24.00 for DVAX, suggesting a potential upside of approximately 136% from the current price. (marketbeat.com)
The company is advancing its pipeline with promising programs, including a shingles vaccine with Phase 1/2 results expected in Q3 2025, a plague vaccine funded by the Department of Defense, and new initiatives in pandemic influenza and Lyme disease vaccines. (stocktitan.net)
Deep Track Capital, holding a 13.5% stake in Dynavax, initiated a proxy fight in February 2025, expressing concerns over the company's focus and governance, which could lead to internal disruptions. (reuters.com)
Despite strong product revenue, Dynavax reported a GAAP net loss of $96.1 million in Q1 2025, primarily due to debt refinancing, raising concerns about financial management. (stocktitan.net)
The company's stock has declined by 22% year-to-date as of June 2025, indicating potential investor skepticism about its growth prospects. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Dynavax Financial Performance
Revenues and expenses
Dynavax Earnings Performance
Company profitability
Dynavax News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dynavax stock?
Dynavax (DVAX) has a market cap of $1.3B as of July 11, 2025.
What is the P/E ratio for Dynavax stock?
The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 0 as of July 11, 2025.
Does Dynavax stock pay dividends?
No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Dynavax dividend payment date?
Dynavax (DVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Dynavax?
Dynavax (DVAX) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.